



## Kidney Transplantation With a Sickle Cell Disease Donor

Carole Philipponnet, Julien Aniort, Cyril Garrouste, Jean-Louis Kemeny, Mohammed Hadj-Abdelkader, Anne-Elisabeth Heng

### ► To cite this version:

Carole Philipponnet, Julien Aniort, Cyril Garrouste, Jean-Louis Kemeny, Mohammed Hadj-Abdelkader, et al.. Kidney Transplantation With a Sickle Cell Disease Donor. *Kidney International Reports*, 2020, 5, pp.1836 - 1838. 10.1016/j.ekir.2020.07.039 . hal-03493175

**HAL Id: hal-03493175**

**<https://hal.science/hal-03493175>**

Submitted on 17 Oct 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **Kidney Transplantation With A Sickle Cell Disease Donor**

Carole Philipponnet, MD (1), Julien Aniort, MD (1,2), Cyril Garrouste, MD (1), Jean-Louis Kemeny, MD, PhD (2,3), Mohammed Hadj-Abdelkader (1) and Anne-Elisabeth Heng, MD, PhD (1,2)

### **Affiliations**

1: Nephrology, Dialysis and Transplantation department, Clermont Ferrand, University

Hospital, Clermont Ferrand, France

2: UFR Medecine, Clermont Ferrand, France

3: Anatomy and Pathology department, Clermont Ferrand, University Hospital, Clermont Ferrand, France

Correspondent: Dr Carole Philipponnet, [cphilipponnet@chu-clermontferrand.fr](mailto:cphilipponnet@chu-clermontferrand.fr)

Address: Nephrology, Dialysis and Transplantation Unit, Clermont Ferrand University Hospital, Clermont Ferrand, France.

Tel: +33 473.751.425

Fax: +33 473.751.183

Key words: kidney transplantation, sickle cell disease, hemosiderin, hemolysis.

### **Author's contribution:**

CP wrote the article. JLK made histological analysis. VFB made alternative. MHA give substantial contributions to the work. JA and CG revising the article critically for important intellectual content. AEH gave final approval of the version published. All Authors read and approved the manuscript.

### **Conflict of interest:**

The authors declare no conflict of interest

### **Disclosure:**

The authors declare no funding was received for this study.

## **INTRODUCTION**

Kidney transplantation is considered as the best treatment for patients with end stage renal disease. The major factor limiting access to transplantation is the shortage of available kidneys. In the vast majority of cases, deceased sickle cell disease (SCD) patients are excluded from kidney donation because of possible renal damage.

We report a case of kidney transplant recipient with SCD donor and highlight that hemosiderin deposits initially presents in epithelial tubular cells disappear few months after stopping exposure to chronic hemolysis. The patient gave his consent to this publication.

## **CASE REPORT**

A seventeen-year-old patient was admitted to the nephrology department for his first kidney transplantation. His main medical antecedents was end stage renal disease requiring chronic hemodialysis secondary to focal and segmental nephropathy. There were no pre-existing immunization to kidney transplantation and no other comorbidities. The donor was a nine-year-old boy with SCD who died due to a cerebral vaso occlusive crises. He suffered from multiple vaso occlusive crises since the age of one year, and from three acute thoracic syndromes having required exsanguino transfusion. The last crisis was complicated by ARDS on acute thoracic syndrome requiring intubation and occlusion of the basilar trunk. There was no acute kidney injury in this patient, the creatinine was steady at  $45\mu\text{mol/L}$ - eGFR  $150\text{ mL/min/1.73m}^2$  CKD EPI with any proteinuria ( $0.02\text{ g/L}$ ). In order to accept the kidney, a preimplantation wedge biopsy processed as a frozen specimen was obtained (Figure 1). This biopsy showed: 1) glomerular enlargement without global segmental sclerosis, no endocapillary hypercellularity and no thrombi; 2)

minimal interstitial fibrosis; 3) no abnormalities in vessels. The only remarkable histologic finding was that of widespread haemosiderosis involving the proximal tubular cells that gave a blue tinge to the specimen on application of Perls' Prussian blue stain. Immunofluorescence was negative. The surgery proceeded without complications; with cold ischemia estimated at 34 hours and warm ischemia at 36 minutes. The immunosuppression protocol was as follows: induction by thymoglobulins, mycophenolate mofetil, corticosteroids and delayed use of calcineurin inhibitors. There was no delayed graft function and the kidney function remained steady with creatinine 130 $\mu$ mol/L- eGFR 80 mL/min/1.73 m<sup>2</sup> CKD –EPI and proteinuria 0.3 g/day. A protocol kidney biopsy was performed at 3 months (Figure 2). In light microscopy, we observed no signs of rejection (no interstitial inflammation, no glomerulitis, and no capillaritis) and haemosiderosis deposits were absent. The immunofluorescence study was negative. One complication occurred during this first year due to a duodenal ulcer. Recipient had a pre-existing iron deficiency at the transplant (ferritin 26  $\mu$ g/L saturation coefficient 16%). Due to the occurrence of post transplant anemia and gastric bleeding, iron supplementation was introduced allowing correction of the deficiency in two months.

## **DISCUSSION**

Sickle cell disease (SCD) is one of the most frequent hereditary hematologic disease in the world. Its most severe and common form results from homozygosity for the mutant form of the gene that encodes beta- globin (1). Mutant sickle beta-globin results from substitution of valine for glutamic acid at its sixth amino acid. The resulting sickle hemoglobin (HbS) polymerizes when the concentration of its deoxygenated form exceeds a critical threshold (1). The long polymers of

deoxygenated HbS distort the red blood cell (RBC) into the characteristic sickle shape, a process that is exquisitely sensitive to the concentration of HbS within the cell. Sickled RBCs have greatly reduced deformability, becoming rigid, which hampers their ability to navigate capillaries and very small blood vessels, leading to occlusion of the microvasculature with subsequent pain, ischemia and organ damage. The pathology of SCD can be directly attributed to HbS polymerization and vaso-occlusion, as well as to secondary effects of chronic hemolysis. In the past few decades, significant advances have been made in our understanding of the complex biochemical and vascular processes that interact with each other to result in vaso-occlusion. Intravascular hemolysis and release of free hemoglobin leading to nitric oxide depletion, endothelial dysfunction, and neutrophil and platelet adhesion are all playing an important contributory role to the pathophysiology of SCD (1-2).

Renal involvement contributes to the diminished life expectancy of patients with SCD, accounting for 16-18 % of mortality (2). The spectrum of renal diseases during SCD includes various renal manifestations such as impairment of urinary concentrating ability, defect in urine acidification, renal papillary necrosis and glomerular injury (2-3). Endothelial dysfunction related to chronic hemolysis and the relative renal hypoxia cause by vaso occlude sickle red blood cells are probably key factors for SCD's renal complications development (2). A retrospective study conducted by 14 pediatric nephrology centers has collected the cases of the adolescents and children with SCD who had a renal biopsy performed from January 2000 to December 2015 (4). Thirty-six SCD patients (ages 4–19 years) were identified; the indications for biopsy were proteinuria (92%) and elevated creatinine (30%). The histopathological findings were mesangial hypercellularity (75%), focal segmental glomerulosclerosis (30%), membranoproliferative glomerulonephritis (16%), and thrombotic microangiopathy

(2%) (4). Another recent observational study included 1251 blacks adults patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years (5). Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease (5). African American donor ethnicity is one of 10 risk factors in calculating the kidney donor profile index used in assessing organ quality. A recent study evaluated outcomes of deceased-donor kidney transplants from African American donors stratified by kidney donor profile index. Inferior graft outcomes in recipients of African American kidneys were limited to those with > 50% kidney donor profile index, probably due to effects of risk factors such as APOL1 risk alleles and sickle cell trait (6). Efforts are made to replace race with APOL1, some recent data suggests a potential interaction with SCD and sickle cell trait.

SCD is viewed as a contraindication to kidney donation. Two kidney transplant recipients from the same SCD donor were recently report (7). They both have delayed graft function requiring 3 days of hemodialysis post transplantation but outcome was favorable. Pre implantation biopsy was performed and there was no evidence of glomerular, vascular or interstitial abnormality (7). The only abnormality seen is the hemosiderin deposits within some of the tubular epithelial cells (7).

Intravascular haemolysis is well known to cause kidney injury by several mechanisms (8). Indeed, intravascular destruction of red blood cells and the resulting accumulation of haemoproteins can induced oxidative stress and cytotoxicity pathways (8).

In 2019, in France, 3,641 kidney transplants were performed, including 508 from living donors. The waiting time on the kidney transplant list is currently estimated between two and five years. In view of this shortage of organs, it was decided to

transplant from the kidney of a donor with SCD which is usually excluded from the donation. This decision was adopted in particular in view of the donor's youth and the absence of a history of kidney injury. In order to support this decision, a pre-implantation renal biopsy was requested and eliminated damage to the renal parenchyma. Perl's staining was subsequently carried out, because the literature reporting an accumulation of iron within the tubular cells of SCD patients.

Of great interest, we were able to obtain a protocol biopsy to assess if there was residual donor derived hemosiderin or transplant damage. We report the disappearance of hemosiderosis deposits in kidney transplant recipient. It is important to note that there were no glomerular or vascular lesions in the preimplantation biopsy and despite the hemosiderin deposits there was no interstitial fibrosis or tubular atrophy. Isolated hemosiderosis deposits are a reversible condition after stopping exposure to chronic hemolysis. Like the two previous patients reported, the outcome was favorable. It is important to emphasize that the donors, in these cases, were children or young adults.

Kidney transplantation with SCD donors seems to be safe with acceptable outcome after a careful examination of donor's clinical history and preimplantation biopsy (Table 1).

**Table 1: TEACHING POINTS:**

- The spectrum of renal diseases during SCD includes various renal manifestations such as impairment of urinary concentrating ability, defect in urine acidification, renal papillary necrosis and glomerular injury
- Isolated hemosiderosis deposits are a reversible condition after stopping exposure to chronic hemolysis.

- Kidney transplantation with SCD donors seems to be safe with acceptable outcome after a careful examination of donor's clinical history and preimplantation biopsy.

## **DISCLOSURES:**

None

## **REFERENCES:**

- 1- Gravitz L, Pincock S. Sick cell disease. *Nature*. 2014 Nov 13;515(7526):S1.
- 2- Nath KA, Hebbel RP. Sick cell disease: renal manifestations and mechanisms. *Nat Rev Nephrol*. 2015 Mar;11(3):161-71
- 3- Cazenave M, Koehl B, Nochy D, Tharaux PL, Audard V. Spectrum of renal manifestations in sick cell disease. *Nephrol Ther*. 2014 Feb;10(1):10-6.
- 4- Zahr RS, Yee ME, Weaver J, Twombly K, Matar RB, Aviles D, Sreedharan R, Rheault MN, Malatesta-Muncher R, Stone H, Srivastava T, Kapur G, Baddi P, Volovelsky O, Pelletier J, Gbadegesin R, Seeherunvong W, Patel HP, Greenbaum LA. Kidney biopsy findings in children with sick cell disease: a Midwest Pediatric Nephrology Consortium study. *Pediatr Nephrol*. 2019 Aug;34(8):1435-1445.
- 5- Olaniran KO, Allegretti AS, Zhao SH, Achebe MM, Eneanya ND, Thadhani RI, Nigwekar SU, Kalim S. Kidney Function Decline among Black Patients with Sick Cell Trait and Sick Cell Disease: An Observational Cohort Study. *J Am Soc Nephrol*. 2020 Feb;31(2):393-404.
- 6- Sureshkumar KK, Chopra B. Impact of Donor Ethnicity on Long-Term Kidney Transplant Outcomes: Analysis by Kidney Donor Profile Index Categories. *Exp Clin Transplant*. 2019 Jun 25.
- 7- Rossidis A, Lim MA, Palmer M, Levine MH, Naji A, Bloom RD, Abt PL. Kidney Transplantation From a Donor With Sick Cell Disease. *Am J Transplant*. 2017 Feb;17(2):569-571.
- 8- Van Avondt K, Nur E, Zeerleder S. Mechanisms of haemolysis-induced kidney injury. *Nat Rev Nephrol*. 2019 Nov;15(11):671-692.

## **LEGENDS:**

### Figure 1: Renal histology (first biopsy)

1A Glomerular enlargement without proliferation, minimal interstitial fibrosis, no abnormalities in vessels. (Masson trichrome stain; original magnification, X 40).

1B Haemosiderin deposits (black arrow) within the proximal tubular cells. (Perls' Prussian blue stain; original magnification, X 20).

### Figure 2: Renal histology (second biopsy)

2A Normal renal histology. (Masson trichrome stain; original magnification, X 20).

2B Disappearance of haemosiderosis deposits. (Perls' Prussian blue stain; original magnification, X 20).







